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Aim: The present study aimed to investigate any possible association between ABO blood groups and lung cancer. Materials and 
Methods: The study was conducted on 122 lung cancer patients and 1,255 matched-healthy individuals that were reviewed retro-
spectively. Chi-square and logistic regression models were used for statistical analysis. Results: No significant difference between 
lung cancer patients and the control group was recorded regarding ABO blood types and the risk of lung cancer (p = 0.055, 
OR = 0.79, 95% CI 0.61–1.03). Male gender (p = 0.006, OR = 2.08, 95% CI 1.24–3.49) and smoking (p = 0.000, OR = 3.13, 
95% CI 1.72–5.69) were significantly associated with the risk of lung cancer. Conclusion: No association between ABO blood types 
and the risk of lung cancer was observed.
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Lung cancer (LC) consists the main cause of can-
cer deaths worldwide and is the second most common 
type of cancer in both genders [1]. Main risk factors 
for LC development are smoking, exposure to environ-
mental and workplace carcinogens, genetic factors 
such as advanced age, male gender, enzymes poly-
morphism and inherited conditions, ionizing radiation 
and previous lung disorders such as chronic obstruc-
tive pulmonary disease, tuberculosis, lung fibrosis and 
other unknown factors [2, 3].
The ABO blood groups system was discovered 
decades ago [4] and its antigens consist biochemi-
cal indices that are expressed in several cell types 
including erythrocytes, gastrointestinal cells, lung 
epithelial cells, mucosa cells etc. [5]. Previous reports 
have recorded that the ABO blood group was associ-
ated with several disorders and pathological condi-
tions, including coronary heart disease [6], ischemic 
stroke [7] and several types of cancer [8, 9], including 
LC [10]. However, the data on the role of ABO blood 
group factor in LC is limited and inconsistent as such 
investigations were limited by their retrospective de-
sign and small case numbers [2, 11–14].
PATIENTS AND METHODS 
122 LC patients and 1,255 healthy individuals were 
assessed retrospectively. ABO blood groups distribu-
tions were similar to those for other Greek population. 
Individuals that were suffered from advanced LC under 
any form of treatment, from cancer in several loca-
tions in which smoking is considered as an obvious 
risk factor such as pharyngeal or larynx cancer, with 
lung metastases because of another primary cancer 
in a different location and those that were diagnosed 
by head-neck-thorax cancer-carcinogenesis field 
theory [15] — were excluded in order to avoid as much 
as possible potential confounding effects on the pa-
rameters examined. The LC patients were diagnosed 
by histological examination whereas the controls were 
selected by the friendly environment of the LC patients 
in an attempt to control possible potential confound-
ers such as the socioeconomic and educational level. 
The following variables: age, gender, smoking status 
(active, former/never), socioeconomic (income/
monthly ≥ 1,000 €), educational level (graduated from 
University/College), history of previous pulmonary 
diseases, such as chronic obstructive pulmonary dis-
ease and LC family history, for the participants were 
estimated, whereas both groups were filled in a self-
administered questionnaire that included information 
regarding the mentioned aspects and data regarding 
their general medical history with reference to medica-
tion and several chronic systemic diseases. For each 
individual the mentioned variables were evaluated 
and coded as dichotomous variables. Chi-square and 
multivariate logistic regression model was carried out 
to investigate the possible associations. Unadjusted 
and adjusted odds ratio’s (OR’s) and 95% confidence 
interval (CI) were also assessed. SPSS ver. 17.0. statis-
tical package was used for the analysis and a p value 
of p < 0.05 was determined as significant statistically.
RESULTS AND DISCUSSION 
The study sample included 680 males and 697 fe-
males ranging in age from 45 to 70+ years old and 
mean age 67 ± 4 years. The distribution of LC patients 
with their histological subtype and the ABO group were 
for squamous LC: A blood group — 42.8%, B — 18.4%, 
AB —10.3%, O — 28.5%, for adenocarcinoma: A blood 
group — 32.3%, B — 11.8%, AB — 8.8%, O — 47.1%, 
for small cell LC: A blood group — 52.0%, B — 8.0%, 
AB — 8.0%, O — 32.0% and for other subtype: A blood 
group — 35.7%, B — 7.1%, AB — 14.3%, O — 42.9%. 
According to univariate analysis the variables age 
(p = 0.000), educational level (p = 0.002, OR = 0.55, 
95% CI 0.38–0.80) and smoking (p = 0.000, OR = 0.40, 
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95% CI 0.26–0.61) were found to be significantly as-
sociated with LC risk.
The primary model showed that smoking (p = 0.000, 
OR = 3.19, 95% CI 1.75–5.84) and male gender 
(p = 0.013, OR = 1.95, 95% CI 1.15–3.29) were sig-
nificantly associated with LC risk whereas ABO blood 
type was not (p = 0.076, OR = 0.77, 95% CI 0.60–1.00). 
According to the final model, smoking (p = 0.000, OR = 
3.13, 95% CI 1.72–5.69) and male gender (p = 0.006, 
OR = 2.08, 95% CI 1.24–3.49) were significantly asso-
ciated with LC risk, whereas no significant association 
between ABO blood type and LC risk was observed 
(p = 0.055, OR = 0.79, 95% CI 0.61–1.03). In the current 
study we investigated the possible association between 
ABO blood group system and the risk of LC develop-
ment. Except for the known etiological and risk factors 
that are associated with LC development, no associa-
tion was observed between those that were examined. 
Recent and previous reports have recorded the impact 
of the ABO blood types in the development of several 
types of cancer, including LC [9] in which it was found 
that blood type other than O was associated with the 
risk of LC, whereas in another study [16] no significant 
association was recorded.
The current study has some limitations. First, 
the study as a retrospective one, has some known 
weaknesses compared to prospective ones, such 
as systemic biases that concerns the sample selection 
and the small number of the cases, and the presence 
of possible confounders. However, further prospective 
studies are needed to clarify the mechanisms by which 
ABO blood type may influence the LC risk. In conclu-
sion, it was recorded that ABO blood type was not 
associated with increased LC risk.
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